98 related articles for article (PubMed ID: 10378701)
21. Targeted liposomal c-myc antisense oligodeoxynucleotides induce apoptosis and inhibit tumor growth and metastases in human melanoma models.
Pastorino F; Brignole C; Marimpietri D; Pagnan G; Morando A; Ribatti D; Semple SC; Gambini C; Allen TM; Ponzoni M
Clin Cancer Res; 2003 Oct; 9(12):4595-605. PubMed ID: 14555535
[TBL] [Abstract][Full Text] [Related]
22. Oblimersen sodium (G3139 Bcl-2 antisense oligonucleotide) therapy in Waldenstrom's macroglobulinemia: a targeted approach to enhance apoptosis.
Frankel SR
Semin Oncol; 2003 Apr; 30(2):300-4. PubMed ID: 12720157
[TBL] [Abstract][Full Text] [Related]
23. c-myb stimulates cell growth by regulation of insulin-like growth factor (IGF) and IGF-binding protein-3 in K562 leukemia cells.
Kim MS; Kim SY; Arunachalam S; Hwang PH; Yi HK; Nam SY; Lee DY
Biochem Biophys Res Commun; 2009 Jul; 385(1):38-43. PubMed ID: 19427836
[TBL] [Abstract][Full Text] [Related]
24. The c-myb proto-oncogene: a novel target for human gene therapy.
Gewirtz AM
Cancer Treat Res; 1996; 84():93-112. PubMed ID: 8724627
[No Abstract] [Full Text] [Related]
25. Clinical use of streptolysin-O to facilitate antisense oligodeoxyribonucleotide delivery for purging autografts in chronic myeloid leukaemia.
Clark RE; Grzybowski J; Broughton CM; Pender NT; Spiller DG; Brammer CG; Giles RV; Tidd DM
Bone Marrow Transplant; 1999 Jun; 23(12):1303-8. PubMed ID: 10414920
[TBL] [Abstract][Full Text] [Related]
26. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
27. Distinct changes in gene expression induced by A-Myb, B-Myb and c-Myb proteins.
Rushton JJ; Davis LM; Lei W; Mo X; Leutz A; Ness SA
Oncogene; 2003 Jan; 22(2):308-13. PubMed ID: 12527900
[TBL] [Abstract][Full Text] [Related]
28. Isolation and functional assessment of common, polymorphic variants of the B-MYB proto-oncogene associated with a reduced cancer risk.
Schwab R; Bussolari R; Corvetta D; Chayka O; Santilli G; Kwok JM; Ferrari-Amorotti G; Tonini GP; Iacoviello L; Bertorelle R; Menin C; Hubank M; Calabretta B; Sala A
Oncogene; 2008 May; 27(20):2929-33. PubMed ID: 18026132
[TBL] [Abstract][Full Text] [Related]
29. Deregulated c-Myb expression in murine myeloid leukemias prevents the up-regulation of p15(INK4b) normally associated with differentiation.
Schmidt M; Koller R; Haviernik P; Bies J; Maciag K; Wolff L
Oncogene; 2001 Sep; 20(43):6205-14. PubMed ID: 11593429
[TBL] [Abstract][Full Text] [Related]
30. The conserved DNA binding domain mediates similar regulatory interactions for A-Myb, B-Myb, and c-Myb transcription factors.
Rushton JJ; Ness SA
Blood Cells Mol Dis; 2001; 27(2):459-63. PubMed ID: 11259168
[TBL] [Abstract][Full Text] [Related]
31. [Autologous bone marrow transplantation for patients with chronic myelogenous leukemia after in vitro purging of the graft with bcr/abl antisense oligodeoxynucleotides].
Sun J; Wu B; Liu Q; Feng R; Liu X; Meng F; Zhou S
Zhonghua Xue Ye Xue Za Zhi; 2000 Aug; 21(8):400-2. PubMed ID: 11877009
[TBL] [Abstract][Full Text] [Related]
32. Use of c-myb antisense oligonucleotides to increase the sensitivity of human colon cancer cells to cisplatin.
Funato T; Satou J; Kozawa K; Fujimaki S; Miura T; Kaku M
Oncol Rep; 2001; 8(4):807-10. PubMed ID: 11410788
[TBL] [Abstract][Full Text] [Related]
33. Apoptosis, Bcl-2 antisense, and cancer therapy.
Piro LD
Oncology (Williston Park); 2004 Nov; 18(13 Suppl 10):5-10. PubMed ID: 15651171
[TBL] [Abstract][Full Text] [Related]
34. [Leukemogenesis and new therapy development: the example of chronic myelogenous leukemia].
Etienne G; Mahon FX
Bull Cancer; 2001 Jul; 88(7):651-8. PubMed ID: 11495816
[TBL] [Abstract][Full Text] [Related]
35. [Antisense oligonucleotides with pharmacologic action].
Tauşer RG; Stoica O
Rev Med Chir Soc Med Nat Iasi; 2003; 107(1):40-5. PubMed ID: 14755968
[TBL] [Abstract][Full Text] [Related]
36. Antisense and nonantisense effects of antisense Bcl-2 on multiple roles of Bcl-2 as a chemosensitizer in cancer therapy.
Kim R; Emi M; Matsuura K; Tanabe K
Cancer Gene Ther; 2007 Jan; 14(1):1-11. PubMed ID: 17041564
[TBL] [Abstract][Full Text] [Related]
37. Integrin receptor-targeted transfer peptides for efficient delivery of antisense oligodeoxynucleotides.
Bachmann AS; Surovoy A; Jung G; Moelling K
J Mol Med (Berl); 1998 Feb; 76(2):126-32. PubMed ID: 9500678
[TBL] [Abstract][Full Text] [Related]
38. Progression to androgen independence is delayed by adjuvant treatment with antisense Bcl-2 oligodeoxynucleotides after castration in the LNCaP prostate tumor model.
Gleave M; Tolcher A; Miyake H; Nelson C; Brown B; Beraldi E; Goldie J
Clin Cancer Res; 1999 Oct; 5(10):2891-8. PubMed ID: 10537358
[TBL] [Abstract][Full Text] [Related]
39. Targeted cancer therapies.
Blay JY; Le Cesne A; Alberti L; Ray-Coquart I
Bull Cancer; 2005 Feb; 92(2):E13-8. PubMed ID: 15749638
[TBL] [Abstract][Full Text] [Related]
40. VP22 light controlled delivery of oligonucleotides to ocular cells in vitro and in vivo.
Normand N; Valamanesh F; Savoldelli M; Mascarelli F; BenEzra D; Courtois Y; Behar-Cohen F
Mol Vis; 2005 Mar; 11():184-91. PubMed ID: 15761390
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
